Compare Bristol-Myers Squibb Co (BMY) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Manulife Financial Corporation — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Manulife Financial Corporation trades at $41.3 (market cap $68.68B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MFC | |
|---|---|---|
Market Cap | $116.30B | $68.68B |
Sector | Health | Financials |
52-Week High | $62.37 | $41.69 |
52-Week Low | $42.60 | $29.90 |
Enterprise Value | $152.24B | $65.24B |
Dividend Yield | 4.42% | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Manulife Financial (MFC) trades at $41.29, unchanged on the day, near its 52-week high. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal steady revenue growth to $53.01B in 2025 and a net income margin of 12.07%. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with 57% buy ratings. Key developments include a dividend payment and AI partnership expansions.
Outlook is cautiously optimistic with growth driven by Asia operations and AI initiatives, but risks include Q1 earnings miss and regulatory scrutiny. Valuation at P/E 16.89 and P/B 2.17 appears reasonable. Investors should monitor execution on earnings recovery and wealth management flows amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
